Opko Biologis

Executive Summary

Opko Biologis is a private Israeli biotech company developing next-generation, long-acting bio-better therapeutics using proprietary CTP, reversible PEGylation, and stabilizer technologies. The company focuses on endocrine and growth disorders, aiming to extend the half-life of proteins and peptides to improve patient compliance and outcomes. Founded in 2013 and having raised approximately $100 million, Opko Biologis is in the commercial stage, though its specific product portfolio and revenue streams are not publicly detailed. The company's platform technology is versatile, potentially applicable to multiple therapeutic areas, and positions it as a player in the growing market for long-acting biologics. However, being private, its financial and pipeline disclosures are limited, which introduces uncertainty about its near-term prospects.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on lead long-acting growth hormone candidate65% success
• Q3 2026Partnership or licensing deal for ex-US commercialization rights70% success
• Q3 2026Initiation of Phase 3 trial for a next-generation CTP-based therapeutic75% success